Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma.

Liudmila V FedorovaKirill V LepikNikita P VolkovPolina V KotselyabinaEvgenia S BorzenkovaMarina O PopovaAnastasia V BeynarovichVadim V BaykovAndrey V KozlovIvan S MoiseevNatalia B MikhailovaAlexander D Kulagin

Published in: International journal of clinical oncology (2021)

Combination of Nivo + BV in r/r cHL after nivolumab monotherapy failure is potentially an effective and safe approach.

Keyphrases

hodgkin lymphoma
combination therapy
open label
lipopolysaccharide induced
lps induced
clinical trial
multiple myeloma